These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 10759663)

  • 1. Doxazosin: a new cytotoxic agent for prostate cancer?
    Cal C; Uslu R; Gunaydin G; Ozyurt C; Omay SB
    BJU Int; 2000 Apr; 85(6):672-5. PubMed ID: 10759663
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines.
    Uslu R; Sanli UA; Sezgin C; Karabulut B; Terzioglu E; Omay SB; Goker E
    Clin Cancer Res; 2000 Dec; 6(12):4957-64. PubMed ID: 11156257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoposide and doxorubicin antagonize the in vitro activity of paclitaxel in human non-small cell lung cancer cell lines.
    Viallet J; Tsao MS; Gallant G
    Lung Cancer; 1996 Aug; 15(1):93-101. PubMed ID: 8865127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
    Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
    Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines.
    Borsellino N; Belldegrun A; Bonavida B
    Cancer Res; 1995 Oct; 55(20):4633-9. PubMed ID: 7553641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro.
    Hahn SM; Liebmann JE; Cook J; Fisher J; Goldspiel B; Venzon D; Mitchell JB; Kaufman D
    Cancer; 1993 Nov; 72(9):2705-11. PubMed ID: 8104682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced activity of estramustine, vinblastine, etoposide, and suramin in prostate carcinoma.
    Arah IN; Dixon SC; Horti J; Figg WD
    Neoplasma; 1999; 46(2):117-23. PubMed ID: 10466436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Doxorubicin-resistant variants of human prostate cancer cell lines DU 145, PC-3, PPC-1, and TSU-PR1: characterization of biochemical determinants of antineoplastic drug sensitivity.
    David-Beabes GL; Overman MJ; Petrofski JA; Campbell PA; de Marzo AM; Nelson WG
    Int J Oncol; 2000 Dec; 17(6):1077-86. PubMed ID: 11078791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel, estramustine, and etoposide in the treatment of hormone-refractory prostate cancer.
    Pienta KJ; Smith DC
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-72-S15-77. PubMed ID: 9346227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic and antagonistic combinations of drugs in human prostate cancer cell lines in vitro.
    Budman DR; Calabro A; Kreis W
    Anticancer Drugs; 2002 Nov; 13(10):1011-6. PubMed ID: 12439335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity- and schedule-dependent interactions of paclitaxel, etoposide and hydroperoxy-ifosfamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines.
    Klaassen U; Harstrick A; Schleucher N; Vanhoefer U; Schröder J; Wilke H; Seeber S
    Br J Cancer; 1996 Jul; 74(2):224-8. PubMed ID: 8688325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of paclitaxel and etoposide in the treatment of lung cancer.
    Perez EA; Buckwalter CA; Reid JP
    Semin Oncol; 1996 Dec; 23(6 Suppl 15):21-5. PubMed ID: 8996593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic interactions between stathmin inhibition and chemotherapeutic agents in prostate cancer.
    Mistry SJ; Atweh GF
    Mol Cancer Ther; 2006 Dec; 5(12):3248-57. PubMed ID: 17172428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-neoplastic activity of topotecan versus cisplatin, etoposide and paclitaxel in four squamous cell cancer cell lines of the female genital tract using an ATP-Tumor Chemosensitivity Assay.
    Boabang P; Kurbacher CM; Kohlhagen H; Waida A; Amo-Takyi BK
    Anticancer Drugs; 2000 Nov; 11(10):843-8. PubMed ID: 11142692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
    Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
    Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergy is documented in vitro with low-dose recombinant tumor necrosis factor, cisplatin, and doxorubicin in ovarian cancer cells.
    Bonavida B; Tsuchitani T; Zighelboim J; Berek JS
    Gynecol Oncol; 1990 Sep; 38(3):333-9. PubMed ID: 2227544
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination study of 1,24(S)-dihydroxyvitamin D2 and chemotherapeutic agents on human breast and prostate cancer cell lines.
    Wigington DP; Urben CM; Strugnell SA; Knutson JC
    Anticancer Res; 2004; 24(5A):2905-12. PubMed ID: 15517895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro assessment of cytotoxic agent combinations for hormone-refractory prostate cancer treatment.
    Cabrespine A; Bay JO; Barthomeuf C; Curé H; Chollet P; Debiton E
    Anticancer Drugs; 2005 Apr; 16(4):417-22. PubMed ID: 15746578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines.
    Kalemkerian GP; Ou X
    Cancer Chemother Pharmacol; 1999; 43(2):145-50. PubMed ID: 9923820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines.
    Giaccone G; Kadoyama C; Maneckjee R; Venzon D; Alexander RB; Gazdar AF
    Int J Cancer; 1990 Aug; 46(2):326-9. PubMed ID: 2166714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.